<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670358</url>
  </required_header>
  <id_info>
    <org_study_id>MC078E</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC078E</secondary_id>
    <secondary_id>RV-NHL-PI-0325</secondary_id>
    <secondary_id>07-007992</secondary_id>
    <secondary_id>NCI-2009-01196</secondary_id>
    <nct_id>NCT00670358</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma</brief_title>
  <official_title>Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer&#xD;
      cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in&#xD;
      different ways. Some block the ability of cancer cells to grow and spread. Others find cancer&#xD;
      cells and help kill them or carry cancer-killing substances to them. Drugs used in&#xD;
      chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving lenalidomide together with rituximab and combination chemotherapy&#xD;
      may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide&#xD;
      when given together with rituximab and combination chemotherapy and to see how well they work&#xD;
      in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large cell&#xD;
      or follicular B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of lenalidomide when given in combination with&#xD;
           rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone in&#xD;
           patients with newly diagnosed stage II-IV diffuse large cell or grade 3 follicular&#xD;
           B-cell lymphoma. (Phase I)&#xD;
&#xD;
        -  To assess the efficacy of this regimen, in terms of event-free survival and response&#xD;
           rate, in these patients. (Phase II)&#xD;
&#xD;
        -  To assess the safety of this regimen in these patients. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the host immune function at baseline and after treatment and correlate these&#xD;
           parameters with tumor response and event-free survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of lenalidomide followed by a&#xD;
      phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride&#xD;
           IV, and vincristine IV on day 1, oral prednisone on days 1-5, and oral lenalidomide on&#xD;
           days 1-10. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment&#xD;
           repeats every 21 days for up to 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive lenalidomide at the maximum tolerated dose determined in&#xD;
           phase I and rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine,&#xD;
           prednisone, and pegfilgrastim as in phase I.&#xD;
&#xD;
      Blood is collected at baseline, before course 3, and after completion of study treatment for&#xD;
      translational research studies. Research studies include immune function and cytokine&#xD;
      analysis, T- and B- quantitative lymphocyte analysis, and single nucleotide polymorphism&#xD;
      analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year, every 4&#xD;
      months for 1 year, and then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 25, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0 (Phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival at 12 months (Phase II)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complete response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune function before and after treatment as assessed by T-, B-, and NK-cell quantification</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of immune function with clinical outcomes</measure>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diffuse large cell or grade 3A/B follicular lymphoma&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Stage II, III, or IV disease&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 lesion ≥ 1.5 cm in one diameter, as detected by CT&#xD;
             scan or PET-CT scan (PET/CT fusion)&#xD;
&#xD;
          -  CD20-positive disease&#xD;
&#xD;
          -  No post-transplant lymphoproliferative disorder (PTLD)&#xD;
&#xD;
          -  No CNS lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN (5 times ULN if direct liver involvement by&#xD;
             lymphoma)&#xD;
&#xD;
          -  AST ≤ 3 times ULN (5 times ULN if direct liver involvement by lymphoma)&#xD;
&#xD;
          -  Creatinine ≤ 2 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use effective double-method contraception for ≥ 28 days&#xD;
             before, during, and for ≥ 28 days after completion of study therapy&#xD;
&#xD;
          -  Fertile male patients must use effective contraception during and for ≥ 28 days after&#xD;
             completion of study therapy, even if they have had a successful vasectomy&#xD;
&#xD;
          -  No blood, sperm, or semen donation during and for ≥ 28 days after completion of study&#xD;
             therapy&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up&#xD;
&#xD;
          -  Willing to provide blood samples for translational research purposes&#xD;
&#xD;
          -  No comorbid systemic illness or other severe concurrent disease that, in the judgment&#xD;
             of the investigator, would preclude study entry or significantly interfere with the&#xD;
             proper assessment of safety and toxicity of the prescribed study regimen&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  Not immunocompromised&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situation that would preclude compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No other active malignancy, except localized nonmelanotic skin cancer or any cancer&#xD;
             that, in the judgment of the investigator, has been treated with curative intent and&#xD;
             will not interfere with the study treatment plan and response assessment&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure requiring ongoing maintenance therapy for life-threatening&#xD;
             ventricular arrhythmias&#xD;
&#xD;
          -  Ejection fraction ≥ 45% by MUGA or ECHO&#xD;
&#xD;
          -  No history of life threatening or recurrent thrombosis/embolism (unless on&#xD;
             anticoagulation therapy during study treatment)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of the bone marrow&#xD;
&#xD;
          -  No concurrent erythroid-stimulating agents (e.g., Procrit, Aranesp)&#xD;
&#xD;
          -  No other concurrent treatment for lymphoma&#xD;
&#xD;
          -  No concurrent radiotherapy, chemotherapy, or immunotherapy for another active&#xD;
             malignancy&#xD;
&#xD;
          -  Able to receive concurrent prophylactic anticoagulation therapy (e.g., low-dose&#xD;
             aspirin [81 mg] daily or an alternative prophylaxis [e.g., warfarin or low molecular&#xD;
             weight heparin])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grzegorz S. Nowakowski, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig B. Reeder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Candido E. Rivera, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judy Olmos, R.N.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Maharaj, R.N.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

